SCHEMBL6549586

SCHEMBL6549586

ClC(Cl)=CCO/N=C/c1cccc(COc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 1/20 0.36
HSP90AA1 P07900 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
XBP1 P17861 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
ADCYAP1R1 P41586 3/20 0.34
SPHK2 Q9NRA0 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549590 1.00 MEN1 (0.36) MEN1KMT2ALMNACYP1A2HSP90AA1
SCHEMBL6548743 0.93 SMN1; SMN2 (0.40) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL6548745 0.93 SMN1; SMN2 (0.40) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL6549302 0.93 LMNA (0.35) MEN1KMT2ALMNACYP1A2HSP90AA1
SCHEMBL6549297 0.93 LMNA (0.35) MEN1KMT2ALMNACYP1A2HSP90AA1
SCHEMBL6548473 0.90 LMNA (0.38) MEN1KMT2ALMNACYP1A2HSP90AA1
SCHEMBL6548478 0.90 LMNA (0.38) MEN1KMT2ALMNACYP1A2HSP90AA1
SCHEMBL6547749 0.90 PPARG (0.36) MEN1KMT2ALMNACYP1A2HSP90AA1
SCHEMBL6547741 0.90 PPARG (0.36) MEN1KMT2ALMNACYP1A2HSP90AA1
SCHEMBL6548050 0.88 KMT2A (0.40) MEN1KMT2ALMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 MEN1 4425/4885KMT2A 2985/4885LMNA 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.